farragutsquaregroup.com

What It Is

Farragut Square Group is a healthcare research and consulting firm with a presence in Washington, D.C. and New York. Its core services focus on regulation, reimbursement, medical auditing, billing and coding, and compliance risk in the U.S. healthcare industry. Its clients mainly include private equity investment firms, healthcare companies, investment banks, and lenders. In 2019, it became part of McDermott+Consulting, the healthcare policy, lobbying, and data analytics consulting arm of McDermott Will & Schulte.

Core Capabilities

Based on publicly available content, Farragut Square Group is not a SaaS or enterprise software provider in the traditional sense, but rather a project-based professional consulting service. Its key capabilities include medical auditing and compliance, reimbursement and regulatory consulting, healthcare transaction due diligence, revenue stability and risk profile assessments, and evaluation of medical billing and coding risks. It covers a wide range of specialties, including dentistry, dermatology, oncology, ophthalmology, cardiovascular care, behavioral health, home health, hospice care, emergency care, laboratories, imaging, urology, women’s health, and more.

Pricing and Delivery

The website does not disclose any packages, subscription pricing, free trials, or standardized product versions. Pricing is likely provided upon request based on project scope, industry segment, and the depth of due diligence required. The site emphasizes that every due diligence project is a “fresh start,” with deliverables customized around client decision-making and partner-level attention provided.

Pros and Cons

Its strengths lie in its highly vertical positioning, directly addressing the most critical regulatory, reimbursement, and compliance risks in U.S. healthcare investing. Client testimonials also highlight its professional depth, responsiveness, and ability to execute under tight timelines. After becoming part of McDermott+Consulting, it may also benefit from synergies in healthcare policy, legal, and data analytics resources. The limitations are also clear: it is not a software platform and lacks SaaS features such as cloud deployment, APIs, permissions, integrations, and automated workflows. Public materials also do not disclose security certifications, methodological details, or transparent pricing.

Who It’s For and Access from China

It is better suited for private equity firms, healthcare groups, banks, and lenders investing in U.S. healthcare assets, particularly for M&A due diligence, compliance audits, reimbursement risk assessment, and optimization of internal compliance systems. For Chinese companies, its relevance is limited unless they are involved in U.S. healthcare market investment or cross-border healthcare operations. The source content does not provide information on website accessibility from China, so this remains unknown.